Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Radiotherapy in Brain Metastases From Drive Gene Negative NSCLC
NCT03801200Phase 2Unknown
- Sponsor
- Hubei Cancer Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), brain metastases, sponsored by Hubei Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT03801200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801200.